Dynamic Change of Peripheral Blood WT1-mRNA within Three Cycles of Azacitidine Therapy Predicts Treatment Response in High-Risk Myelodysplastic Syndrome
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-138377
Abstract: Introduction. Hypomethylating agents azacitidine (AZA) and decitabine are standard of care for myelodysplastic syndromes (MDS). Considering the result of the secondary analysis of the AZA-001 trial showing 91% of first responses occurred within 6 cycles,… read more here.
Keywords: wt1 mrna; response; three cycles; cycles aza ... See more keywords